Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults

Approval based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and extensive nonclinical development program.REZZAYO...

Related Keywords

Japan ,Germany ,San Diego ,California ,United States ,Oliver Cornely ,Brian Ritchie ,Veronica Eames ,Taylor Sandison ,Data Review Committee ,Cidara Therapeutics Inc ,European Union ,Exchange Commission ,Nasdaq ,University Hospital ,Securities Exchange ,European Medicines Agency ,European Excellence Centre For Medical Mycology ,European Commission ,Globenewswire Inc ,Committee For Medicinal Products Human Use ,Lifesci Communications ,Medicines Agency ,Medicinal Products ,Human Use ,Excellence Centre ,Medical Mycology ,Chief Medical Officer ,Orphan Drug Designation ,License Agreement ,Prescribing Information ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Quarterly Report ,Markets ,